Posted by Michael Wonder on 21 Oct 2020
ICER posts draft scoping document for the assessment of Alzheimer’s disease
21 October 2020 - Document open to public comment until 10 November 2020.
The Institute for Clinical and Economic Review has posted a draft scoping document outlining a planned review of the comparative clinical effectiveness and value of aducanumab (Biogen) for Alzheimer’s disease.
The FDA is expected to make a decision on aducanumab in early 2021.
